key: cord-1010259-1peg3502
authors: Cohen, Kristen W.; Linderman, Susanne L.; Moodie, Zoe; Czartoski, Julie; Lai, Lilin; Mantus, Grace; Norwood, Carson; Nyhoff, Lindsay E.; Edara, Venkata Viswanadh; Floyd, Katharine; De Rosa, Stephen C.; Ahmed, Hasan; Whaley, Rachael; Patel, Shivan N.; Prigmore, Brittany; Lemos, Maria P.; Davis, Carl W.; Furth, Sarah; O’Keefe, James; Gharpure, Mohini P.; Gunisetty, Sivaram; Stephens, Kathy A.; Antia, Rustom; Zarnitsyna, Veronika I.; Stephens, David S.; Edupuganti, Srilatha; Rouphael, Nadine; Anderson, Evan J.; Mehta, Aneesh K.; Wrammert, Jens; Suthar, Mehul S.; Ahmed, Rafi; McElrath, M. Juliana
title: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
date: 2021-07-03
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100354
sha: 0366e3f65bdcc2bc4a0a0377b86aa47cecdd60b9
doc_id: 1010259
cord_uid: 1peg3502

Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to eight months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.

The COVID-19 pandemic caused by the rapid spread of SARS-CoV-2, a novel 72 betacoronavirus, continues to cause significant morbidity and mortality. The induction of 73 effective early immune control of SARS-CoV-2 and durable immune memory is critical 74 to prevent severe disease and to protect upon re-exposure. SARS-CoV-2 infection 75 induces polyclonal humoral and cellular responses targeting multiple viral proteins 76 described in cross-sectional and longitudinal studies. 1 More comprehensive, 77 quantitative analyses with extensive serial sampling in larger numbers of patients are limited, and could resolve some conflicting views about the durability of 79 humoral immunity. Importantly, defining the frequency, immune function and specificity 80 of the antibodies, memory B and T cell responses among COVID-19 patients, and 81 identifying when they appear and how long they persist can provide understanding of 82 the integral components for long-lived immunity to SARS-CoV-2 and potentially other 83 human coronaviruses that emerge in the future. 2 84

We initiated two prospective COVID-19 patient cohorts in Seattle and Atlanta during 85 the first surge of the pandemic to investigate long-term immunity to SARS-CoV-2. 86

Among 254 COVID-19 patients enrolled and frequently sampled, we identify binding 87 and neutralizing antibodies to SARS-CoV-2 as well as antigen-specific B and T cells 88 elicited early after infection, define their specificities, quantify the extent of antibody 89 boosting of cross-reactive responses to other coronaviruses, and further characterize 90 the decay rate and durability of these immune parameters over 250 days. We employ 91 highly standardized or validated assays that are also being used to evaluate immunity in 92 recent and ongoing clinical vaccine trials. [3] [4] [5] This indepth longitudinal study 93 demonstrates that durable immune memory persists in most 94 including those with mild disease, and serves as a framework to define and predict long-95 lived immunity to SARS-CoV-2 after natural infection. This investigation will also serve 96 as a benchmark for immune memory induced in humans by SARS-CoV-2 vaccines. 97

COVID-19-confirmed patients were recruited into our longitudinal study of SARS-101

CoV-2 specific B and T cell memory after infection. A total of 254 patients enrolled at 102 two sites, Atlanta and Seattle, starting in April 2020 and returned for follow up visits over 103 a period of 250 days. We were able to collect blood samples at 2-3 time points from 165 104 patients and at 4-7 time points from another 80 patients, which allowed us to perform a 105 longitudinal analysis of SARS-CoV-2-specific B and T cell responses on a large number 106 of infected patients. The demographics and baseline characteristics of this cohort are 107 described in Table S1 . The study group was 55% female and 45% male and between 108 18-82 years old (median, 48.5 years). Based on World Health Organization (WHO) 109 guidelines of disease severity, 71% of study participants exhibited mild disease, 24% 110 had moderate disease, and 5% experienced severe disease. 111

We next examined if SARS-CoV-2 infection had any impact on the levels of 180 antibodies to the other human coronaviruses. We measured IgG, IgA, and IgM antibody 181 binding to the spike proteins of other known human coronaviruses in the COVID-19 182 patients (n=222 for IgG and n=190 for IgA and IgM) and compared these data to the 51 183 pre-pandemic healthy donor samples. In the COVID-19 patients, IgG and IgA antibodies 184 to the alphacoronaviruses, 229E and NL63, did not show any significant changes 185 compared to the antibody levels in the pre-pandemic healthy controls (Figure 2A against HKU1 and OC43 betacoronaviruses are common in adults, pre-existing CoV-1 exposure is rare and antibody levels to SARS-CoV-1 spike protein were very low 195 (essentially negative) in the pre-pandemic healthy controls. However, SARS-CoV-1 196 spike-reactive antibodies increased significantly after SARS-CoV-2 infection. These 197 increases were quite striking for IgG (p=0.0038) and also IgA (p=0.0084) and most likely 198 represent cross-reactive antibodies directed to SARS-CoV-2 spike epitopes that are 199 conserved between SARS-CoV-2 and SARS CoV-1 14 . These newly induced cross- ranged from <20 to 3726 ( Figure 3A ). Of the 183 individuals for whom longitudinal 212 neutralization titers were assayed, 140 (77%) had at least one timepoint with 213 neutralization titers above the limit of detection (>20). Seventy-five percent (43/57) of 214 COVID-19 patients generated serum neutralizing antibodies between 30 -50 days after 215 symptom onset, and similarly 72% (48/67) had measurable titers between 180 -263 216 days after symptom onset. Using an exponential decay model, we evaluated the 217 kinetics of neutralizing antibody titers after day 42 and estimated a half-life of 150 days 218 (95%CI [124, 226] ). However, similar to the spike reactive IgG binding antibodies, we 219 hypothesized that the neutralizing antibody rate of decay may actually slow over time 220 during the recovery period. To address this, we fit a power law to the data. The power 221 law model fit significantly better than the exponential decay model (ΔAIC=9) and 222 estimated the half-life of neutralizing antibody responses at 120 days post-symptom 223 onset to be 254 days (95%CI [183, 400] ). 224

Next, we assessed the relationship between the levels of spike and RBD binding 225 antibodies and SARS-CoV-2 neutralization. Figures 3B and C show the SARS-CoV-2 226 spike and RBD binding antibody response kinetics of the 183 participants for whom 227 neutralization titers were assessed. These exhibited a wide range of antibody binding 228 levels ranging from non-responders (n=11) who did not elicit antibody titers above those 229 of pre-pandemic controls (defined as a COVID-19 patient titer below the mean pre-230 pandemic antibody titer plus 3 standard deviations, see dashed line on Figure 3B , C) to 231 those with IgG levels >200,000 AU/ml. Spike and RBD binding IgG levels correlated 232 significantly with the neutralization titers ( Figure 3D contribute to viral control by generating antibody responses upon re-exposure to the 242 pathogen. We used full-length spike and RBD antigen probes to quantify the 243 frequencies of SARS-CoV-2 spike-and RBD-specific MBC in longitudinal PBMC 244 samples from 111 COVID-19 patients ( Figure 4 ) and from 29 pre-pandemic controls 245 ( Figure S3A , B). Our flow cytometric gating strategy to identify SARS-CoV-2 specific 246 MBC and classify them as IgG, IgM and IgA MBC isotypes is shown in Figure 4A . 247 Among the total MBC, the spike IgG+ MBCs were significantly increased in COVID-248 19 patients (n=111; Figure 4B ) in comparison to pre-pandemic controls (n=29; Figure  249 S3A) (median increase, 0.73% vs. 0.02%; p<0.0001). After a steep early expansion 250 over the first 2-3 months, the spike IgG+ MBC persisted in COVID-19 patients with no 251 decline out to 250 days post symptom onset. These findings ( Figure 4B The spike IgM+ MBC appeared within the first two weeks post-symptom onset and 255 quickly declined ( Figure 4C , D). The decay continued after day 30 (slope=-0.007, 256 95%CI [-0.010, -0.005], p<0.001). One month after symptom onset, 56% of spike MBC 257 were IgG+, which increased to a peak of 80% at 5-6 months ( Figure 4D ). Circulating 258 spike IgA+ MBC were also detectable in many subjects at low frequencies and without 259 significant change over time (day 30 to 250: slope=0.000, 95%CI [-0.002, 0.002], 260 p=0.91, Figure 4D ). 261

Since the RBD contains the primary neutralizing epitopes on the spike, we also 262 used an RBD-specific probe to characterize this subset of spike-specific memory B 263 cells. Overall, approximately 20% of the spike IgG+ memory B cells targeted the RBD, 264 which was consistent across subjects and time ( Figure 4E, F Figure 4E ). Thus, the maintenance of circulating spike-and RBD-specific IgG 268 memory B cells suggests that these cells could be recruited for a rapid secondary 269 response following re-exposure or vaccination. patients and uninfected controls using a high-dimensional, multi-parameter ex vivo 278 intracellular cytokine staining (ICS) assay. The assay is sensitive, precise and specific 279 for detection of antigen-specific T cells expressing multiple cytokines and effector 280 molecules following a short-term (6 hours) stimulation with peptide pools. Our lab 281 developed and validated the assay, and we are currently using the method to quantitate 282 Th1/Th2 CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccine trials. Here, we 283 assessed T cell responses to the SARS-CoV-2 structural (S, E, M and N) and 284 accessory proteins (ORF 3a, 6, 7a, 7b, and 8) using overlapping peptide pools that 285 span the sequences of these proteins. 286

Among COVID-19 patients, 89% (102/113) mounted CD4+ T cell responses ( Figure  287 5A) recognizing at least one SARS-CoV-2 structural protein that was detectable at one 288 or more visits. By contrast, SARS-CoV-2 specific CD4+ T cells were rarely detected in 289 the uninfected control group using this assay ( Figure To better characterize the development of T cell memory in SARS-CoV-2 infection, 298

we examined the differentiation profiles of virus-specific T cells longitudinally in COVID-299 19 patients. Based on CD45RA and CCR7 expression, SARS-CoV-2-specific CD4+ T 300 cells were primarily central memory phenotype (CD45RA-CCR7+) and to a lesser 301 extent effector memory (CCRA-CCR7-); this profile of the memory T cell subsets was 302 very consistent between subjects and stable over time ( Figure 5B ). The antigen-specific 303 CD4+ T cells were Th1-biased with a predominant CXCR3+CCR6-phenotype, and 304 highly polyfunctional, with simultaneous detection of antigen-specific CD154, IFN-γIL-305 2, TNF-αand less frequently granzyme B in the early expansion phase (21-60 days post 306 symptom onset; median, 30 days) ( Figure 5C ). Interestingly, many of the virus-specific 307 CD4+ T cells also exhibited this polyfunctionality at the memory time point (>180 days 308 post symptom onset; median, 203 days) ( Figure 5D ). Circulating SARS-CoV-2-specific 309 Th2 (IL-4, IL-5 and IL-13), Th17 (IL-17) or perforin-expressing subsets were not 310 detected Figure 5C and D). 311

Next, we examined the CD8+ T cell responses in COVID-19 patients and found that 312 69% generated CD8+ T cells recognizing at least one SARS-CoV-2 structural protein 313 that were detectable at one or more visits ( Figure 6A ), in contrast to infrequent to rare, 314 low-level antigen specific responses in the uninfected control donors ( Figure S3D ). 315

Expansion of CD8+ T cells occurred over the first month and then frequencies gradually 316 declined, with a half-life of 196 days (95%CI [92, 417] ) and a negative estimated slope 317 after 30 days of symptom onset (slope=-0.004, 95%CI [-0.002, -0.008], p<0.0001) 318

( Figure 6A ). The median frequency of SARS-CoV-2-specific CD8+ T cells was 0.2%, 319 indicating a lower overall response magnitude than observed for CD4+ T cells. 320

However, like the CD4+ T cells, a wide range in magnitudes was observed with many 321 SARS-CoV-2-specific CD8+ T cell frequencies above 1% and even up to 12% ( Figure 6B ). A small but stable fraction of SARS-CoV-2-specific 332 CD8+ T cells expressed a central memory phenotype (slope=0.024, p=ns; Figure 6B ). 333

The SARS-CoV-2-specific CD8+ T cells were highly polyfunctional with the highest 334 magnitude populations secreting IFN-γ, TNF-α and granzyme B; other dominant 335 subsets also expressed IL-2 or perforin ( Figure 6C , D). This polyfunctional profile was 336 seen in the expansion phase (median 30 days; Figure 6C ) and also at the later time 337 points (>180 days post symptom onset; median 203 days; Figure 6D ). It is important to 338 note that this pattern of CD8+ T cell differentiation has been described in detail after 339 vaccination in humans with the live attenuated yellow fever virus vaccine (YFV-17D). 15 340

This YFV-17D vaccine generates long-lived and functional virus specific memory CD8+ 341 T cells that persist in humans for decades. 15, 16 That the CD8+ T cell differentiation 342 program after COVID-19 infection resembles what is seen after YFV infection of human 343 suggests that COVID-19 patients may also generate long-lived CD8+ T cell memory. 344

The majority of COVID-19 patients generated CD4+ T cells that recognized most 347 SARS-CoV-2 viral structural and accessory proteins, with the highest percentage 348 responding to S2 (78%) and S1 (69%) ( Figure cell response rate was directed to the nucleocapsid (57%), followed by ORFs 7a, 7b, 355 and/or 8 (25%), S1 (25%), ORFs 3a and/or 6 (16%), S2 (12%) and E and/or M (9%) 356 ( Figure 6E ). Also, among the COVID-19 patients with CD8+ T cell responses, there was 357 a bias with the largest percentage (median, 43%) reacting to the nucleoprocapsid 358 protein ( Figure 6F ). While SARS-CoV-2 CD8+ T cell responses rates were much lower 359 in uninfected controls, when present in a few control donors with lower frequencies, 360 these were also targeted to the nucleocapsid protein ( Figure S3D ). A likely explanation 361 for these findings is that in SARS-CoV-2 infection, antigen-presenting cells in vivo may 362 display a higher proportion of peptides derived from the nucleocapsid protein and hence 363 more nucleocapsid-specific CD8+ T cells are generated during infection. This has 364 interesting implications suggesting that nucleocapsid-specific CD8+ T cells might be 365 more efficient in recognizing virally infected cells. 366 367 Age and disease severity are significantly associated with magnitude of SARS-368

We evaluated whether COVID-19 patient age, disease severity, or gender could 370 account in part for the heterogeneity observed among the SARS-CoV-2-specific 371 immune responses as estimated from the individual models (post day 30 for cellular and 372 post day 42 for antibody responses). We observed that age was significantly associated 373 with higher immune responses to SARS-CoV-2, independently of any covariation with 374 disease severity ( Figure 7A ). Neutralizing antibody titers and IgG antibody responses to 375 nucleocapsid increased 1.35-fold and 1.25-fold, respectively, with each decade of age 376 and the same disease severity (95%Cis [1.19, 1.54] and [1.08, 1.43], p values<0.003). 377

Similarly, increased age positively correlated with increased frequencies of spike and 378 RBD-specific IgG+ memory B cells, with 1.19 to 1.24-fold higher responses per decade 379 of age (p values<0.02; Figure 7A ), accounting for disease severity. Increased age also 380 correlated with higher SARS-CoV-2 and S1-specific CD4+ T cell responses (1.16-1.20-381 fold increase by decade of age, p values<0.02) and N-specific CD8+ T cell responses 382

(1.24-fold increase by decade of age, p=0.039) accounting for disease severity ( Figure  383 7A). 384

Since the cohort included primarily persons with mild to moderate COVID-19, we 385 had limited ability to assess the relationship of severe disease and SARS-CoV-2 386 immune responses, especially among the cellular responses. However, we found that 387 after accounting for age, severe disease (WHO score >4) was associated with higher 388 IgG antibodies to nucleocapsid, spike, RBD, and NTD ( Figure 7B , C), and SARS-CoV-2 389 neutralization titers ( Figure 7D ). Severe disease was also associated with 2.30 to 2.46-390 fold higher S1, E and/or M, and nucleocapsid-specific CD4+ T cells (all p values<0.05; 391 Figure 7B ). We found no significant relationships between gender and the immune 392 responses evaluated, apart from 1.66-fold higher IgG NTD responses antibodies among 393 males compared to females, after accounting for age and disease severity (95%CI 394 [1.08, 2.55], p=0.022). In all, our analyses suggest that there are synergistic, but also 395 independent mechanisms driving higher adaptive immune responses in COVID-19 396 patients who are older and/or who experienced more severe disease. 397 398

We assessed correlations between SARS-CoV-2-specific immune responses using 401 the individual-level models to interpolate the magnitude of responses for each 19 patient at early (day 30) or later (day 180) convalescent time points ( Figure 7E ). We Establishing immune memory is essential in the defense against SARS-CoV-2 417 infection. To end the COVID-19 pandemic, it is critical to know how long immunity 418 against SARS-CoV-2 will persist after infection and whether it will be sufficient to 419 prevent new infections and severe disease in years to come. Identifying in depth the 420 adaptive immune components leading to recovery and modeling the trends of each 421 response was enabled by the longitudinal sampling of a large number of COVID-19 422 patients. Here, we show that most convalescent COVID-19 patients mount durable 423 antibody, B and T cells specific for SARS-CoV-2 up to 250 days, and the kinetics of 424 these responses provide an early indication for a favorable course ahead to achieve 425 long-lived immunity. Because the cohort will be followed for 2-3 more years, we can 426 build on these results to define the progression to long-lived immunity against this novel 427 human coronavirus, which can guide rational responses when future outbreaks occur. 428

The hallmark of the initial immune defense against SARS-CoV-2 is the emergence 429 of antibodies recognizing the SARS-CoV-2 spike protein, including the RBD and NTD 430 components of the S1 subunit, during the early phase of viral replication. These The durable antibody responses in the COVID-19 recovery period are further 464 substantiated by the ongoing rise in both the spike and RBD memory B cell responses 465 after over 3-5 months before entering a plateau phase over 6-8 months. Persistence of 466 RBD memory B cell has been noted. [25] [26] [27] We presume this may be explained by 467 sustained production of memory B cells in germinal centers of lymph nodes draining the 468 respiratory tract in the early months, followed by the memory B cell redistribution into 469 the circulation as the germinal centers begin to recede. Thus, the induction and 470 maintenance of memory B cells and, over time, long-lived plasma cells, will continue to 471 furnish higher affinity antibodies if re-exposures occur. 472

In contrast to spike memory B cell kinetics, SARS-CoV-2-specific CD4+ and CD8+ 473 memory T cells each peak early, within the first month, but then slowly decline over the 474 next 6-7 months. Central memory Th1-type CD4+ T cells dominate throughout the early 475 infection and recovery period. However, the CD8+ T cells exhibit a predominant 476 effector memory phenotype early that transitions to those effector memory cells re-477 expressing CD45RA, maintaining expression of antiviral cytokines and effector functions 478 which have been shown to provide protective immunity against other viral pathogens. 479

We also provide clear evidence that the CD4+ T cells mount a broader antigen-specific 480 response across the structural and accessory gene products, whereas the CD8+ T cells 481 are predominantly nucleocapsid specific and spike-specific responses are substantially 482 lower in frequency. 483

Our study demonstrates the considerable immune heterogeneity in the generation 484 of potentially protective response against SARS-CoV-2, and by focusing on the 485 dynamics and maintenance of B and T cell memory responses, we were able to identify 486 features of these early cellular responses that can forecast the durability of a potentially 487 effective antibody response. The ability to mount higher frequencies of RBD-specific 488 memory IgG+ B cells early in infection was the best indicator for a durable RBD-specific 489

IgG antibody and neutralizing antibody response. In addition, higher frequency CD4+ T 490 cells were associated with stronger spike IgG and neutralizing antibody responses. 491 However, the induction and peak response of SARS-CoV-2-specific CD8+ T cells 492 occurs independently to these antibody responses. Interestingly, while it has been 493 widely reported that age correlates with COVID-19 disease severity, we found that age 494 and disease severity were independent co-variates associated with the magnitude of 495 both SARS-CoV-2-specific CD4+ T cell and humoral SARS-CoV-2 immunity, but not 496 with the magnitude of CD8+ T cell responses. In the case of T cells, whether the T cell 497 differences are related to the frequencies or specificities of pre-existing coronavirus 498 CD4+ and CD8+ T cell immunity will require additional future analysis. 499

The COVID-19 pandemic remains a global public health threat after one year of 500 overwhelming disruption and loss. Overcoming the challenges to end the pandemic is 501 accentuated by the recognition that SARS-CoV-2 can undergo rapid antigenic variation 502 that may lower vaccine effectiveness in preventing new cases and progression to 503 severe disease. 24, 28, 29 Our findings show that most COVID-19 patients induce a wide-504 ranging immune defense against SARS-CoV-2 infection, encompassing antibodies and 505 memory B cells recognizing both the RBD and other regions of the spike, broadly-506 specific and polyfunctional CD4+ T cells, and polyfunctional CD8+ T cells. The immune 507 response to natural infection is likely to provide some degree of protective immunity 508 even against SARS-CoV-2 variants because the CD4+ and CD8+ T cell epitopes will 509 likely be conserved. Thus, vaccine induction of CD8+ T cells to more conserved 510 antigens such as the nucleocapsid, rather than just to SARS-CoV-2 spike antigens, may 511 add benefit to more rapid containment of infection as SARS-CoV-2 variants overtake 512 the prevailing strains. 513 514

Our study evaluates COVID-19 patients only up to 8 months and requires models to 516 estimate immune response half-lives thereafter. Because our longitudinal study will 517 extend beyond two years, we can corroborate our models with subsequent experimental 518 data on the persistence of immune memory. Our study population was primarily 519 outpatients with mild to moderate COVID-19 and thus we were unable to evaluate 520 immune memory in those with the extreme presentations, both asymptomatic and 521 severe COVID-19. However, mild-moderate illness accounts for >80% of COVID-19 522 cases 30 , highlighting the relevance of our findings over time. 

This study did not generate new unique reagents. 694

The underlying data for this paper will be shared by the lead contact upon request 696 without restriction. 697

Two longitudinal COVID-19 cohort studies at Fred Hutchinson Cancer Research 701

Center (Seattle, Washington) and Emory University (Atlanta, Georgia) began after 702 receiving institutional review board approvals (IRB 10440, IRB 00001080 and 703 IRB00022371). Adults ≥18 years were enrolled who met eligibility criteria for SARS-704

CoV-2 infection and provided informed consent. Study participants provided medical 705 history of co-morbidities, presentation of SARS-CoV-2 infection onset and disease 706 course, and peripheral blood at initial and follow up visits for analysis of serum antibody 707 and cellular immune responses. Additional longitudinal archived sera and PBMC from 708 pre-pandemic study populations from Emory and Seattle served as controls for the 709 immune assays. 710

The Atlanta study population included adult volunteers over the age of 18 who were 711 diagnosed with COVID-19 by a commercially available SARS CoV-2 PCR assay, rapid 712 antigen test, or clinical syndrome only (later confirmed with serology) due to limited 713 SARS-CoV-2 testing during the early period of the pandemic. Ambulatory participants 714 were recruited through local advertisements, internet-based avenues (such as social 715 media, listserves), COVID-19 testing sites, and primary care clinics. Hospitalized 716 patients were identified through SARS-CoV-2 testing. Informed consent was obtained 717 from all participants prior to conduct of study procedures. Initial acute peripheral blood 718 samples were collected from hospitalized patients at the time of enrollment. 719

Convalescent samples from hospitalized patients were collected when the patients were 720 able to return for a visit to the clinical research site at the next study visit. Serial 721 peripheral blood samples were collected starting at about 30 days after the onset of 722 COVID-19 symptoms and/or after PCR positivity for SARS-CoV-2. Thereafter, samples 723 were collected at 3, 6, and 9 months. The study is ongoing with expected completion of 724 sample collection from participants in February 2023. Participants were excluded if they 725 were immunocompromised, HIV positive, had active hepatitis B or C virus infection, 726 used immunosuppressive drugs for 2 weeks or more in the preceding 3 months, 727 received blood products or immune globulin 42 days prior to enrollment, received 728 convalescent COVID-19 plasma, or were pregnant or breast feeding. We report on 110 729 participants to date, of which 73% were diagnosed by SARS-CoV-2 PCR, the remaining 730 were diagnosed by rapid antigen test or serology. Demographic features of the 731 participants are as follows: median age was 48; 45% were male; the majority (80%) 732 were white, 11% Black/African American, 6% Asian, and 8% were Hispanic/Latinx 733 ethnicity. The most frequent co-morbid conditions were hypertension, obesity, heart 734 disease and diabetes mellitus. The most frequent COVID-19 symptoms were 735 myalgia/fatigue, fever, cough, headache, loss of smell and taste (Table S1) . 736

Hospitalized patients were older, with a median age of 56; a higher percentage were 737

Black/African American (27%); and 100% had fever. The Seattle COVID-19 Cohort study participants were recruited from the Seattle 745 metropolitan area by social media advertisements, partnership with the local emergency 746 medical service and by word of mouth. Study participants were screened and enrolled 747 by the Seattle Vaccine Trials Unit staff. Eligibility criteria included adults at risk for 748 SARS-CoV-2 infection or those diagnosed with COVID-19 by a commercially available 749 SARS-CoV-2 PCR assay or blood antibody test and willing to have at least four blood 750 draws collected over one year. Exclusion criteria included pregnancy and inability to 751 donate blood. 752

Informed electronic consent was obtained from all Seattle participants during a 753 screening phone call with study clinical staff. Interested participants were screened, 754 consented and medical history and COVID-19 illness onset date and symptoms 755 collected. Participants undiagnosed with COVID-19 had a nasopharyngeal (NP) swab 756 collected and tested for SARS-CoV-2 via an FDA-approved PCR test and blood was 757 collected for SARS-CoV-2 antibody (Abbott) and study assays. Those with either a 758 positive PCR or antibody test were asked to return for future blood draws. Those who 759 tested negative were asked to return as controls for the positive cohort and in case they 760 tested positive in the future. Participants with a positive test prior to study enrollment or 761 those diagnosed in study were asked to provide blood donation at approximately 7 762 days, 2 weeks, 1, 2, 3, 4, 6, 9-and 12-months post symptom onset. After completing 763

one year of study, participants will be given the option of continuing the longitudinal 764 study for up to two or more years. At each study visit, participant symptoms and medical 765 history is updated. Those with COVID-19 symptoms after enrollment in all groups are 766 offered a nasopharyngeal swab PCR SARS-CoV-2 test. 

Neutralization assays with SARS-CoV-2 virus were performed as previously described 815 [33] [34] [35] . Plasma/serum were serially diluted (three-fold) in serum-free Dulbecco's modified 816

Eagle's medium (DMEM) in duplicate wells and incubated with 100-200 FFU infectious 817 clone derived SARS-CoV-2-mNG virus at 37°C for 1 hr 33 . The antibody-virus mixture 818 was added to VeroE6 cell (C1008, ATCC, #CRL-1586) monolayers seeded in 96-well 819 blackout plates and incubated at 37°C for 1 hr. Post-incubation, the inoculum was 820 removed and replaced with pre-warmed complete DMEM containing 0.85% 821 methylcellulose. Plates were incubated at 37°C for 24 hr. After 24 hr, methylcellulose 822 overlay was removed, cells were washed twice with PBS and fixed with 2% 823 paraformaldehyde in PBS for 30 min at room temperature. Following fixation, plates 824 were washed twice with PBS and foci were visualized on a fluorescence ELISPOT 825 reader (CTL ImmunoSpot S6 Universal Analyzer) and enumerated using Viridot 36 . The 826 neutralization titers were calculated as follows: 1 -(ratio of the mean number of foci in 827 the presence of sera and foci at the highest dilution of respective sera sample). Each 828 specimen was tested in two independent assays performed at different times. The 829

FRNT-mNG 50 titers were interpolated using a 4-parameter nonlinear regression in 830 GraphPad Prism 8.4.3. Samples with an FRNT-mNG 50 value that was below the limit of 831 detection were plotted at 20. probes were made at a ratio of 1:1 molar ratio of trimer to SA. Two S6P probes, one 839 labeled with AlexaFluor488 (Invitrogen), one labeled with AlexaFluor647 (Invitrogen), 840

were used in this panel in order to increase specificity of the detection of SARS-CoV-2-841 specific B cells. The RBD probe was prepared at a 4:1 molar ratio of RBD monomers to 842 SA, labeled with R-phycoerythrin (Invitrogen). Cryopreserved PBMCs from SARS-CoV-843 2-convalescent participants and a pre-pandemic SARS-CoV-2-naïve donor were 844 thawed at 37°C and stained for SARS-CoV-2-specific memory B cells as described 845

previously 19 with a panel of fluorescently-labeled antibodies (see Key Resource Table) . Table.  858 Peptide pools covering the structural proteins of SARS-CoV-2 were used for the six-859 hour stimulation. Peptides matching the SARS-CoV-2 spike sequence (316 peptides, 860 plus 4 peptides covering the G614 variant) were synthesized as 15 amino acids long 861 with 11 amino acids overlap and pooled in 2 pools (S1 and S2) for testing 862 (BioSynthesis). All other peptides were 13 amino acids overlapping by 11 amino acids 863 and were synthesized by GenScript. The peptides covering the envelope (E), 864 membrane (M) and nucleocapsid (N) were initially combined into one peptide pool, but 865 the majority of the assays were performed using a separate pool for N and one that 866 combined only E and M. Several of the open reading frame (ORF) peptides were 867 combined into two pools: ORF 3a and 6, and ORF 7a, 7b and 8. All peptide pools were 868 used at a final concentration of 1 μg/ml for each peptide. As a negative control, cells 869

were not stimulated, only the peptide diluent (DMSO) was included. As a positive 870 control, cells were stimulated with a polyclonal stimulant, staphylococcal enterotoxin B 871 (SEB). Cells expressing IFN-γ and/or IL-2 and/or CD154 was the primary 872 immunogenicity endpoint for CD4+ T cells and cells expressing IFN-γ was the primary 873 immunogenicity endpoint for CD8+ T cells. The overall response to SARS-CoV-2 was 874 defined as the sum of the background-subtracted responses to each of the individual 875 pools. A sample was considered positive for CD4+ or CD8+ T cell responses to CoV-2 if any of the CD4+ or CD8+ T cell responses to the individual peptide pool 877 stimulations was positive. Positivity was determined using MIMOSA 40 . The total number 878 of CD4+ T cells must have exceeded 10,000 and the total number of CD8+ T cells must 879 have exceeded 5,000 for the assay data to be included in the analysis. 880

Binding and neutralizing antibody responses 883

Mixed effects exponential and power law models were used to analyze waning of 884 antibody (day 42 to day 263 post symptom onset). For binding antibody analyses, 885 antibody (Ab) was natural log transformed, yielding linear equations of the form 886 ln(Ab)=a+b*(day-42) and ln(Ab)=a+b*ln(day/42) for the exponential and power law 887 models, respectively, and fit using the lmer function (lme4 package) in R. Models 888 included population level fixed effects and individual level random effects for intercept 889 and slope and covariance between the random effects. Simplified modelswith random 890 effects only for interceptwere also fit. Neutralization antibody data were analyzed in 891 Monolix (Lixoft). For analysis in Monolix, the exponential and power law models were 892 formulated as ordinary differential equations, dAb/dt=k*Ab and dAb/dt=k*Ab/t, 893 respectively, with antibody at day 42 lognormally distributed and lognormal multiplicative 894 error. Neutralization titers < 20 were treated as left censored. For comparison of 895 models, difference in Akaike information criterion (ΔAIC) > 4 was considered statistically 896 significant. Models (in R and Monolix) were fit using maximum likelihood. To account for 897 repeated measures, correlations between antibody binding levels and neutralization 898 titers were calculated using a repeated measures correlation (rmcorr package) in R 41 . 899 900 B cell responses 901

We considered linear mixed effects models for B cell response, , as a function of , 902 the ℎ time since symptom onset for the ℎ individual, with random effects for intercept 903 and slope and > 30 days for all , : 904 log ℯ = 0 + 1 + where 0 = 0 + and 1 = 1 + with ( , ) iid ~ 2 ( , ), with 905 906 responders, and the other component modeled the non-responders. The parameters 927 defining these distributions, as well as the probabilities that each ICS response was 928 either a responder or non-responder, were estimated from the observed data. This 929 sharing of information across SARS-CoV-2 responders and non-responders increased 930 the sensitivity and specificity to make positivity calls 42 . Responses with probability of 931 response > 0.999 were considered positive responders. 932

We considered nonlinear mixed effects models for T cell response, , as a function of 933 , the ℎ time since symptom onset for the ℎ individual, with random effects for 934 intercept and slope and > 30 days for all , : and 2 and 2 are the between-person variation in the intercept and slope of log T cell 937 responses respectively, and iid ~ (0, 2 ). The random effects, and , 938 are each assumed to be independent for different individuals and the within-individual 939 errors are assumed to be independent for different i, j and to be independent of the 940 random effects. The function nlme from the R package nlme was used to fit the models. 941

Diagnostic plots of residuals were examined to assess validity of the model 942 J o u r n a l P r e -p r o o f

Adaptive immunity to SARS-CoV-2 and COVID-966 19

COVID-19 and the Path to Immunity

Antibody Persistence through 6 Months after the Second Dose of mRNA-972 1273 Vaccine for Covid-19

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in 976 Older Adults

Interim 979 Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

The time course 982 of the immune response to experimental coronavirus infection of man

Seasonal 986 coronavirus protective immunity is short-lasting

Immunological characteristics 989 govern the transition of COVID-19 to endemicity

Humoral Immunity 992 Due to Long-Lived Plasma Cells

Duration of antiviral immunity after 996 smallpox vaccination

Lifetime of plasma cells in the 998 bone marrow

Duration of humoral 1000 immunity to common viral and vaccine antigens

Influenza vaccine-induced human bone marrow plasma cells decline 1005 within a year after vaccination

Decoding Covid-19 with the SARS-CoV-2 Genome

Origin and differentiation of human memory CD8 T cells after vaccination

Immune Response to Yellow Fever Vaccination in Human Immunodeficiency 1016 Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: 1017 Implications for Vaccination Schedule. Clinical infectious diseases : an official 1018 publication of the Infectious Diseases Society of America

Structure, Function, and Antigenicity of the SARS-CoV

Human neutralizing antibodies elicited by SARS-CoV-2 1025 infection

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent 1029 Neutralizing Antibodies with Limited Somatic Mutation

Potently 1033 neutralizing and protective human antibodies against SARS-CoV-2

Dynamics and turnover of memory CD8 T cell responses following yellow fever 1038 vaccination

Evolution of 1041 immune responses to SARS-CoV-2 in mild-moderate COVID-19

SARS-CoV-2 infection 1045 induces long-lived bone marrow plasma cells in humans

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-1050

CoV-2 infection

Evolution of antibody immunity to SARS-CoV-2

Immunological memory to 1057 SARS-CoV-2 assessed for up to 8 months after infection

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild 1062 COVID-19

SARS-CoV-2 Viral 1064 Variants-Tackling a Moving Target

Infection-1068 and vaccine-induced antibody binding and neutralization of the B

CoV-2 variant

Characteristics of and Important Lessons 1072 From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of 1073 a Report of 72314 Cases From the Chinese Center for Disease Control and 1074 Prevention

Defining antigen-specific plasmablast and memory B cell subsets in human blood 1078 after viral infection or vaccination

An Infectious cDNA 1086 Clone of SARS-CoV-2

Development of a Rapid Focus Reduction Neutralization Test Assay for 1091 Measuring SARS-CoV-2 Neutralizing Antibodies

Viridot: An automated virus plaque (immunofocus) counter for the measurement 1100 of serological neutralizing responses with application to dengue virus

Structure-1104 based design of prefusion-stabilized SARS-CoV-2 spikes

OMIP-056: Evaluation of Human Conventional T 1108

Donor-Unrestricted T Cells, and NK Cells Including Memory Phenotype by 1109

Optimization and validation of an 1112 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T 1113 cells induced by vaccination

Mixture models for single-cell assays with 1117 applications to vaccine studies

Repeated Measures Correlation. Front 1120 Psychol 8

Detecting 1122 differential gene expression with a semiparametric hierarchical mixture method

Most recovered COVID-19 patients mount broad, durable immunity after infection  Neutralizing antibodies show a bi-phasic decay with half-lives >200 days  Spike IgG+ memory B cells increase and persist post-infection  Durable polyfunctional CD4 and CD8 T cells recognize distinct viral epitope regions eTOC SUMMARY

Cohen et al evaluate immune responses longitudinally in 254 COVID-19 patients over 8 months. SARS-CoV-2-specific binding and neutralizing antibodies exhibit biphasic decay, suggesting long-lived plasma cell generation. Memory B cells remain stable; CD4 and CD8 memory T cells are polyfunctional. Thus, broad and effective immunity may persist long-term

and 2 and 2 are the between-person variation in the intercept and slope of log B cell 907 responses respectively, Cov(b, c) is the covariance between the intercept and slope, 908 and iid ~ (0, 2 ). The random effects, and , are each assumed to be 909 independent for different individuals and the within-individual errors are assumed to 910 be independent for different i, j and to be independent of the random effects. The 911 function lme from the R package nlme was used to fit the models.